Supplementary Methods from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

Authors :: Richard S. Finn
Dennis J. Slamon
James G. Christensen
Ian Taylor
Carolyn D. Britten
David J. Cohen
Lee Anderson
Charles Ginther
Neil A. O'Brien
Amrita J. Desai
Dylan Conklin
Ondrej Kalous
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: PDF file, 55K.

Full Text Access

Tools